U.S. Life Sciences Stock News

The J. M. Smucker Company recently reported fiscal 2026 third-quarter results showing higher net sales of US$2,339.4 million but a larger net loss of US$724.2 million, alongside slightly narrowed full-year net sales guidance of 3.5% to 4.0% growth and projected diluted EPS in the range of US$1.89 to US$1.39 loss. At the same time, Smucker moved to strengthen its governance and product portfolio by adding two financially experienced independent directors following engagement with Elliott...

If you are wondering whether Jack Henry & Associates is fairly priced at its recent levels, you are not alone. This article focuses squarely on what you are paying versus what you are getting. The stock most recently closed at US$164.20, with a 5.5% return over the last 7 days but declines of 8.4% over 30 days, 7.9% year to date and 6.5% over 1 year, while the 3 year and 5 year returns sit at 3.7% and 15.3% respectively. These mixed returns have kept valuation questions on the table, and...

If you are wondering whether MSCI is fairly priced or offering an opportunity right now, it helps to step back and look closely at what the current share price really reflects. The stock last closed at US$573.88, with recent returns of 6.6% over 7 days, a 5.8% decline over 30 days, 1.5% year to date, a 1.2% decline over 1 year, 9.6% over 3 years and 50.4% over 5 years. Taken together, these figures give a mixed picture of recent momentum and risk sentiment. Recent news around MSCI has...

If you are wondering whether Supernus Pharmaceuticals at around US$55.09 is still offering value after its recent run, you are not alone. The stock has posted returns of 8.7% over the past 7 days, 14.4% over 30 days, 11.4% year to date and 73.6% over 1 year, with longer term returns of 43.5% over 3 years and 116.0% over 5 years. These moves sit against a backdrop of continuing interest in Supernus Pharmaceuticals as a neurology focused drug maker. Investors are paying close attention to how...

ACM Research delivered its first 300mm single wafer cleaning systems to a major foundry in Singapore, marking an entry into Southeast Asia. The company secured new advanced packaging equipment orders from leading global semiconductor customers. ACM Research completed a private share offering intended to support further product development and international expansion. ACM Research (NasdaqGM:ACMR), trading at $57.11 at the last close, has been attracting attention with a very large 3 year...

Gold Royalty has upsized and amended its credit facility, securing reduced interest rates. The updated facility is intended to provide greater financial flexibility for future opportunities. Partners operating assets tied to Gold Royalty’s royalties and streams have reported progress on production ramp ups, expansions, drilling, feasibility work, and project milestones. Gold Royalty (NYSEAM:GROY) is drawing investor attention after a series of financing and asset updates, with shares...

If you are wondering whether Aramark is fairly priced today or if there is still room for value, this article walks through what the numbers are actually saying about the stock. The share price recently closed at US$41.26, with returns of 1.7% over 7 days, 7.2% over 30 days, 12.8% year to date and 15.9% over 1 year, plus 3 year and 5 year returns of 51.7% and 43.7% respectively. Recent news coverage around Aramark has largely focused on its position in the outsourced services and facilities...

First Interstate BancSystem (FIBK) has come under pressure after hotter than expected inflation data and rising credit risk concerns pushed regional bank shares lower. This has prompted investors to reassess sector valuations and risk exposure. See our latest analysis for First Interstate BancSystem. The recent easing of inflation and credit concerns follows a mixed period for the stock, with a 7.32% 90-day share price return and a 22.14% 1-year total shareholder return contrasting with...

Danaos (DAC) has just filed an omnibus shelf registration, covering potential offerings of common and preferred stock, debt securities, warrants and other instruments, a move that gives management broad future financing flexibility. See our latest analysis for Danaos. The shelf registration comes after a strong run in the shares, with a 7 day share price return of 8.95% and a year to date share price return of 24.18%. The 1 year total shareholder return of 58.92% and 5 year total shareholder...

AtriCure (ATRC) just reported fourth quarter and full year 2025 results that show higher sales and a shift to quarterly profitability, along with 2026 guidance that calls for revenue growth and positive full year net income. See our latest analysis for AtriCure. Even with the stronger quarterly results and 2026 guidance, AtriCure’s recent share price performance has been weak. The 30 day share price return shows a 16.25% decline and the 1 year total shareholder return reflects a 20.61% loss,...

Crane NXT (CXT) recently hosted its Analyst and Investor Day, giving the market an updated look at its operations after reporting 10% year over year sales growth and higher full year sales growth guidance. See our latest analysis for Crane NXT. At a share price of $48.66, Crane NXT’s short term share price return has been weak, with a 13.11% decline over 90 days and a 9.70% fall in 1 year total shareholder return, while the Antares Vision acquisition and higher sales growth guidance keep...

If you are wondering whether V2X at around US$70.97 is still offering value or already pricing in a lot of optimism, you are not alone. The stock has returned 4.5% over the last 7 days, 3.1% over the last month, 27.7% year to date and 55.0% over the past year, which naturally raises questions about what is already baked into the current price. Recent coverage has focused on V2X as a capital goods company listed on the NYSE under the ticker VVX. Investors are paying close attention to how it...

If you are wondering whether TransDigm Group's current share price fairly reflects the business, this article is designed to help you think through that question step by step. The stock last closed at US$1,316.26, with returns of 1.6% over 7 days, a 7.8% decline over 30 days, a 3.1% decline year to date, 2.6% over 1 year, 99.9% over 3 years and 161.2% over 5 years. Recent share price moves sit against a backdrop of ongoing interest in TransDigm Group as a major US capital goods name...

Sionna Therapeutics (SION) is back on traders’ radar after a recent share price pullback, with the stock down about 20% over the past month and around 13% over the past 3 months. See our latest analysis for Sionna Therapeutics. Those recent declines come after a very strong run, with a 1 year total shareholder return of about 135% and a current share price of US$33.92. This suggests momentum has cooled as investors reassess growth potential and risk around the CF pipeline. If Sionna’s swings...

If you are looking at Medical Properties Trust and wondering whether the current share price reflects its underlying worth, you are not alone. The stock closed at US$5.65 recently, with returns of 12.5% over the last 30 days, 11.2% year to date and 4.4% over the past year, set against longer term 3 year and 5 year returns of 28.9% and 60.3% declines. Recent headlines around Medical Properties Trust have focused on its balance sheet, portfolio repositioning and how it is responding to a...

CareTrust REIT (NYSE:CTRE) has moved into the UK healthcare real estate market through the acquisition of Care REIT plc. The transaction expands CareTrust REIT's portfolio and marks its first international platform outside the US. The company has also scaled its structured finance activities alongside large portfolio acquisitions. CareTrust REIT is taking a bigger swing with this UK entry, adding a new geography on top of its existing US footprint. The stock last closed at $40.89, with a 1...

Winnebago Industries (NYSE:WGO) is working through persistent RV industry headwinds as sales have fallen over the past two years. Despite reporting revenue growth, the company has seen profitability weaken, pointing to rising pressure on its core business. This combination of softer sales trends and thinner margins is drawing attention to deeper challenges across the recreational vehicle sector. For you as an investor, Winnebago sits at the intersection of discretionary spending and outdoor...

In February 2026, Tronox Holdings plc reported fourth-quarter 2025 sales of US$730 million and a net loss of US$176 million, with full-year 2025 sales of US$2.90 billion and a net loss of US$470 million, before subsequently filing an omnibus shelf registration for ordinary shares, preference shares, and debt securities. The combination of widening losses and a new universal shelf registration highlights Tronox’s need for financial flexibility at a time of rising earnings pressure and...

Kosmos Energy (NYSE:KOS) has secured extensions for major Ghana oil and gas licenses to 2040. The company is reshaping its portfolio, including acquiring a key FPSO, exiting Equatorial Guinea assets, and focusing on the Gulf of Mexico via a new alliance with Shell. Management is targeting a 20% reduction in operating costs and a 10% reduction in net debt in 2026, supported by new bond financing. Kosmos Energy, trading at $2.4, has seen sharp share price swings, with the stock up 16.5% over...

Why EnerSys is on investors’ radar EnerSys (ENS) has drawn attention after recent trading reflected a mix of short term pressure and longer term strength, prompting investors to reassess how its current share price lines up with recent returns. See our latest analysis for EnerSys. At a share price of $165.97, EnerSys has seen some recent pressure, including a 7.89% 1 month share price return. However, its 14.68% 3 month share price return and 69.60% 1 year total shareholder return point to...

SiriusPoint Ltd. has reported its fourth-quarter and full-year 2025 results, with quarterly revenue rising to US$973.7 million and net income reaching US$244 million, while full-year revenue climbed to US$3.21 billion and net income to US$459.6 million, alongside sharply higher earnings per share from continuing operations. On the same day, the Board of Directors announced it will consider a share repurchase program, a move that could meaningfully influence capital allocation, per-share...

In late February 2026, FIGS, Inc. reported fourth-quarter 2025 revenue of US$201.9 million and net income of US$18.51 million, capping a full-year performance of US$631.1 million in sales and US$34.25 million in net income with sharply higher earnings per share versus 2024. Management paired these results with an outlook for 10% to 12% revenue growth in 2026, underscoring momentum from a larger active customer base, international expansion and improved operating margins. We’ll now examine...

In late February 2026, California Water Service Group reported that fourth-quarter 2025 sales eased to US$219.98 million and net income fell to US$11.48 million, with full-year 2025 sales of US$1,000.14 million and net income of US$128.21 million, reflecting lower water consumption and higher costs. At the same time, the company accelerated its expansion by agreeing to acquire Nexus Water Group’s Nevada and Oregon systems and the remaining interest in its Texas joint venture, while...

Aardvark Therapeutics recently voluntarily paused its Phase 3 HERO trial of ARD-101 for hyperphagia in Prader-Willi Syndrome, and no longer expects to report topline data in the third quarter of 2026, with updated guidance now planned for the second quarter of 2026. The pause affects Aardvark’s lead asset in a rare disease setting where ARD-101 already holds both Orphan Drug and Rare Pediatric Disease designations from the FDA. We will now examine how the pause of the HERO Phase 3 trial for...